ForeseeHome™ - AMD Monitoring Program

Management Team

Quinton Oswald - Chief Executive Officer

Mr. Oswald brings extensive ophthalmic development and commercialization experience to Notal Vision, previously holding CEO positions with Neurotech and SARcode Bioscience.  Prior to that, he was responsible for the successful launch of Lucentis® at Genentech, and led the U.S. and Canada marketing efforts for Visudyne® as the Sr. Vice-President for North America Ophthalmology at Novartis.    

Susan Orr, O.D. - Chief Medical Officer & VP Medical Affairs

Dr. Orr has over 19 years of ophthalmic and retina strategy, development, and operational experience.  Prior to joining Notal Vision, Dr. Orr served as Leader of Global Medical Affairs, Strategy, and Search & Evaluation for the Ophthalmology franchise at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, and held key R&D and marketing leadership positions during her 17 year tenure at Alcon, a Novartis company.

Gidi Benyamini - General Manager, Notal Vision, Ltd.

Mr. Benyamini has over 13 years of experience in Ophthalmology Prior to joining Notal Vision, he was VP of Engineering and Manufacturing at LaserComm, a telecommunications company based in Dallas, Texas. Prior to that, he held various positions in the Israeli hi-tech industry.

Scott Jones - Chief Commercial Officer

Mr. Jones has over 25 years of experience in the pharmaceutical, biotech, and device industries. He has held several senior management positions in sales, marketing, reimbursement, and government affairs while at Novartis and QLT.

Shirley Kleinman - Chief Financial Officer

Prior to joining Notal Vision, Ms. Kleinman worked in Management consulting & the start-up industry in Israel. She holds a BA in economics and sociology From Tel Aviv University and an MBA from IE Business School.

Jim Niebanck - VP Marketing & Sales

Mr. Niebanck has over 25 years of experience in sales, marketing and operational leadership positions most recently as Head of Strategy and Operations at Novartis prior to joining Notal Vision.  During Mr. Niebanck's tenure at Novartis, he was also responsible for marketing Visudyne®.

Muki Rapp, Ph.D. - VP Research & Development

Dr. Rapp has over 14 years of experience in heading R&D projects in Ophthalmology. Prior to joining Notal Vision, he worked as a senior SW engineer in several start-up companies. He holds a Ph.D. and M.Sc. in neuroscience and a B.Sc. in computer science from the Hebrew University of Jerusalem.